The demand for point of care testing (POCT) is increasing across the globe because of the growing aging population, rising prevalence of chronic diseases, and lifestyle changes. POCT is the performance of a test nearby to the site of the patient care for providing immediate results outside the traditional laboratory environment. In addition to this, diagnostic companies, such as Alere, Abaxis, and Cepheid, have started recognizing the potential of quick molecular diagnostic testing, which why they have launched various point of care products that are based on microfluidic technology in the past few years. This, in turn, is expected to drive the requirement for microfluidic devices.